|
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Hires Heikki Jouttijarvi as chief technical officer, saying he has decades of experience in biopharma manufacturing, supply chain management and commercial operations. Chief Executive Officer Juho Jalkanen says: ‘His wealth of experience with commercial operations, manufacturing and supply chain management with late-stage and approved drugs is incredibly valuable for us as we progress with bexmarilimab to the announced phase IIb trial in higher-risk myelodysplastic syndromes’. Bexmarilimab is an investigational immunotherapy designed to overcome resistance to existing treatments, among others. Myelodysplastic syndromes are a type of blood cancer. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
